Home › NCT06282510
Nasal Antisepsis for C. Auris Prevention
RecruitingPhase 4
Impact of Nasal Antisepsis on Candida Auris Colonization
Who can join
Ages 18 and older · All sexes
Full eligibility criteria
Inclusion Criteria: * History of C. auris colonization or infection * Patient in a participating facility Exclusion Criteria: * History of severe allergy to iodine-based products, defined as anaphylaxis or rash * Currently breastfeeding or pregnant * Non-English language speaking
About the study
This is a randomized, controlled, open-label trial of effect of 10% povidone iodine intranasal antisepsis on the detection of Candida auris.
What is being tested
- Povidone Iodine Topical (drug)
Sponsor: Mary K Hayden · Participants: 120 · Started: Jan 29, 2024
Contact the study team
- Sarah E. Sansom, DO · Phone: 3125636201
- Mary K. Hayden, MD · Phone: 3129428727
Official record on ClinicalTrials.gov — NCT06282510
Locations in the U.S.
| Illinois | RML Specialty Hospital, Chicago Rush University Medical Center, Chicago RML Specialty Hospital, Hinsdale |
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.